


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	Jason Peter Brown	
Appln. No.:	10/511,515	
Filed:	October 15, 2004	Examiner:
Title:	METHOD FOR PRODUCING IMMORTALISED ANTIBODIES-SECRETING CELLS	Group Art Unit:

SECOND PRELIMINARY AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

I hereby certify that this document is being sent via First Class mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on this 14th day of December, 2005.


(Signature)

Sir:

This paper is in response to the Notification of Missing Requirements mailed October 17, 2005 for the above-identified application. Please amend the application as follows and consider the following remarks.

Amendments to the specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.

Amendments to the Specification

Please insert the attached paper copy of the Sequence Listing into the Specification immediately preceding the claims.

REMARKS

Submitted herewith are paper and computer readable forms of the Sequence Listing for the above-identified application. The content of the paper and computer readable forms is identical and contains no new matter.

Favorable consideration of all pending claims is earnestly solicited.

Respectfully submitted,

DORSEY & WHITNEY LLP

Date: December 14, 2005

By: 
Janet M. MacLeod (Reg. No. 35,263)
DORSEY & WHITNEY LLP
250 Park Avenue
New York, New York 10177-1500
(212) 415-9366

US 10-511515 SEQ LIST.txt
SEQUENCE LISTING

<110> Brown, Jason P
<120> Methods for producing antibodies
<130> 211389US sequence listing
<140> PCT/GB03/01650
<141> 2003-04-16
<150> GB 0208819.3
<151> 2002-04-17
<160> 16
<170> PatentIn Ver. 2.1
<210> 1
<211> 29
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: DNA primer
<220>
<221> primer_bind
<222> (1)..(29)
<223> 5' VgEcR-RXR DNA primer containing SpeI
restriction enzyme recognition site.
<400> 1
gtactagtag ggatttttggt catggctag

<210> 2
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:DNA primer
<220>
<221> primer_bind
<222> Complement((1)..(30))
<223> 3' VgEcR-RXR DNA primer containing SpeI
restriction enzyme recognition site.
<400> 2
gtactagtca gctggttcct tccgcctcag

<210> 3
<211> 36
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:DNA primer
<220>

29

30

<221> primer_bind
 <222> (1)..(36)
 <223> 5' c-myc DNA primer containing NheI restriction enzyme recognition site.

 <400> 3
 gtagctagcg ccaccatgcc cctcaacgtg aacttc 36

 <210> 4
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:DNA primer

 <220>
 <221> primer_bind
 <222> Complement((1)..(30))
 <223> 3' c-myc DNA primer containing XhoI restriction enzyme recognition site.

 <400> 4
 gatctcgagt tatgcaccag agtttcgaag 30

 <210> 5
 <211> 36
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:DNA primer

 <220>
 <221> primer_bind
 <222> (1)..(36)
 <223> 5' abl DNA primer containing NheI restriction enzyme recognition site.

 <400> 5
 gtagctagcg ccaccatgga gcctggtgga gttggc 36

 <210> 6
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:DNA primer

 <220>
 <221> primer_bind
 <222> Complement((1)..(30))
 <223> 3' abl DNA primer containing XhoI restriction enzyme recognition site.

 <400> 6
 gatctcgagt caagcttgct gtccaagatc 30

US 10-511515 SEQ LIST.txt

<210> 7
 <211> 37
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:DNA primer

 <220>
 <221> primer_bind
 <222> (1)..(37)
 <223> 5' SV40 Large T DNA primer containing NheI
 restriction enzyme recognition site.

 <400> 7
 gtagctagcg ccaccatgga tagagttctg agcagag 37

 <210> 8
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:DNA primer

 <220>
 <221> primer_bind
 <222> Complement((1)..(30))
 <223> 3' SV40 Large T DNA primer containing XhoI
 restriction enzyme recognition site.

 <400> 8
 gatctcgagt caataaactg tgtattcagc 30

 <210> 9
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:DNA primer

 <220>
 <221> primer_bind
 <222> (1)..(30)
 <223> 5' pIND DNA primer containing SpeI restriction
 enzyme recognition site.

 <400> 9
 gtactagttg ccacctgacg tcgacggatc 30

 <210> 10
 <211> 29
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:DNA primer

 <220>

```

<221> primer_bind
<222> Complement((1)..(29))
<223> 3' pIND DNA primer containing SpeI restriction
      enzyme recognition site.

<400> 10
gtactagtct cagaagccat agagcccac
29

<210> 11
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:DNA primer

<220>
<221> primer_bind
<222> (1)..(32)
<223> 5' beta-globin DNA primer.

<400> 11
ccaatctgct cacacaggat agagagggca gg
32

<210> 12
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:DNA primer

<220>
<221> primer_bind
<222> Complement((1)..(32))
<223> 3' beta-globin DNA primer.

<400> 12
ccttgaggct gtccaagtga ttcaggccat cg
32

<210> 13
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:DNA primer

<220>
<221> primer_bind
<222> (1)..(21)
<223> 5' c-myc transgene confirmation DNA primer.

<400> 13
acagcttcga aactctggtg c
21

<210> 14
<211> 21
<212> DNA

```

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA primer

<220>

<221> primer_bind

<222> (1)..(21)

<223> 5' abl transgene confirmation DNA primer.

<400> 14

agctgccctg cacctttcct g

21

<210> 15

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA primer

<220>

<221> primer_bind

<222> (1)..(21)

<223> 5' Large T transgene confirmation DNA primer.

<400> 15

aacttgctc ctccgatgct c

21

<210> 16

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:DNA primer

<220>

<221> primer_bind

<222> (1)..(21)

<223> 5' VgEcR-RXR transgene confirmation DNA primer.

<400> 16

cagctgcatt ctcccatcag c

21

Applicant: Jason Peter Brown

Title: METHOD FOR PRODUCING
IMMORTALISED ANTIBODIES-
SECRETING CELLS

Saved to Disk: December 13, 2005

OS: Windows NT

Ref. No. 185875/US

Filing Date: December 14, 2005

Serial No.: 10/511,515



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/511,515	Jason Peter Brown	185875/US

30873
 DORSEY & WHITNEY LLP
 INTELLECTUAL PROPERTY DEPARTMENT
 250 PARK AVENUE
 NEW YORK, NY 10177

INTERNATIONAL APPLICATION NO.

PCT/GB03/01650

I.A. FILING DATE


PRIORITY DATE

04/16/2003

04/17/2002

CONFIRMATION NO. 4660

371 FORMALITIES LETTER



OC000000017247183

Date Mailed: 10/17/2005

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 10/15/2004
- Copy of the International Search Report filed on 10/15/2004
- Preliminary Amendments filed on 10/15/2004
- Information Disclosure Statements filed on 10/15/2004
- Biochemical Sequence Listing filed on 10/15/2004
- Request for Immediate Examination filed on 10/15/2004
- U.S. Basic National Fees filed on 10/15/2004
- Priority Documents filed on 10/15/2004

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$130 for a Large Entity:

- **\$130 Surcharge.**

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

FREDERICK SMITH

Telephone: (703) 308-9140 EXT 210

PART 1 - ATTORNEY/APPLICANT COPY


U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/511,515	PCT/GB03/01650	185875/US

VENDOR ID: 35196

VENDOR NAME: Commissioner of Patents

CHECK DATE: 12/13/05

INVOICE NO.	INV. DATE	INVOICE DESCRIPTION	AMOUNT PAID
J. MacLeod	12-13-05	M. Beauchamp - 18th Floor	130.00
CONTROL NO.: 600677			TOTAL \$130.00



600677 091000022104773898556

Exhibit 3

**Copy of Return Receipt Postcard bearing OIPE stamp of DEC 19, 2005
Attorney Docket No. 376956-003US (368532)
Serial No. 10/511,515**

Patent Mail Received

DEC 27 2005

475213-3

The mail stamp of the United States Patent and Trademark Office on this return receipt postcard acknowledges the filing on the date stamped of the following:

Response to Notification of Missing Requirements, Declaration and Power of Attorney, Preliminary Amendment, Paper and computer readable copies of Sequence Listing, Copy of Notification of Missing Requirements and check for \$130.00.

Via First Class Mail

First Named Inventor: Jason Peter Brown

Client Name: Page White & Farrer

Application No.: 10/511,515

Filing Date: October 15, 2004

Application Title: METHODS FOR PRODUCING IMMORTALISED
ANTIBODIES-SECRETING CELLS

Attorney Initials: JMM

Mailed: 12/14/05

Docket No.: 185875/US




Exhibit 4

**Copy of Revocation and Power of Attorney and Electronic
Acknowledgment Receipt dated July 26, 2006
Attorney Docket No. 376956-003US (368532)
Serial No. 10/511,515**

Electronic Acknowledgement Receipt	
EFS ID:	1129293
Application Number:	10511515
Confirmation Number:	4660
Title of Invention:	Methods for producing immortalised antibodies-secreting cells
First Named Inventor:	Jason Peter Brown
Customer Number:	30873
Filer:	Ann Maria Pease./Patti Selan
Filer Authorized By:	Ann Maria Pease.
Attorney Docket Number:	185875/US
Receipt Date:	26-JUL-2006
Filing Date:	
Time Stamp:	20:12:47
Application Type:	U.S. National Stage under 35 USC 371
International Application Number:	

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Power of Attorney (may include Associate POA)	Power.pdf	81370	no	2

Warnings:	
Information:	
Total Files Size (in bytes):	81370
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jason Peter Brown

Serial No.: 10/511,515

Filed: October 15, 2004

For: METHODS FOR PRODUCING
IMMORTALISED ANTIBODIES-
SECRETING CELLS

Docket No: 376956-003US (368532)

Confirmation No.: 4660

Group Art Unit: Unknown

Examiner: Unknown

COMBINED REVOCATION AND POWER OF ATTORNEY AND STATEMENTS
UNDER 37 CFR §§ 3.73(B) & 3.71 AND REQUEST FOR CHANGE OF
ATTORNEY DOCKET NUMBER

Granta Biotechnology Limited, a corporation organized and existing under the law of Great Britain, states that it is:

1. ☒ the assignee of the entire right, title and interest; *or*
2. ☐ an assignee of _____% of the entire right, title and interest

in the above-captioned patent application by virtue of either:

A. ☒ an assignment from the inventor(s) of the above-captioned application ☒ recorded in the United States Patent and Trademark Office at Reel 017122, Frame 0001, or ☐ for which a true copy thereof is attached hereto; *or*

B. ☐ a chain of title from the inventor(s) of the above-captioned application to _____, Inc. as shown below:

1. From the inventor(s) to _____, Inc., recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or ☐ for which a true copy thereof is attached hereto; and

2. From _____, Inc. to _____, Inc., recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or ☐ for which a true copy thereof is attached hereto; and

3. From _____, Inc. to _____, Inc., recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or ☐ for which a true copy thereof is attached hereto.

☒ As required by 37 CFR § 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to Granta Biotechnology Limited was, or concurrently is being, submitted for recordation pursuant to 37 CFR § 3.11.

☐ The undersigned hereby authorizes insertion of the recordation information, including Reel and Frame No., when it becomes available, after the document has been executed.


Granta Biotechnology Limited hereby revokes all previous powers of attorney and hereby appoints **Ann M. Caviani Pease**, Registration No. 42,067, and the **Dechert LLP** attorneys and agents associated with **Customer Number 37509** as its attorneys with full power of substitution and revocation, to prosecute the above-captioned application and to transact all business in the Patent and Trademark Office connected therewith connected therewith, including full power of association, substitution, and revocation, said appointment being to the exclusion of the inventor(s) and his/her attorney(s) in accordance with the provisions of 37 CFR § 3.71; provided that if any one of said attorneys ceases to be affiliated with the law firm of Dechert LLP as partner, employee or of counsel, such attorney's appointment as attorney and all powers derived therefrom shall terminate on the date such attorney ceases being so affiliated.

Please direct all correspondence in the captioned application to:

Customer No. 37509
Dechert LLP
PO Box 10004
Palo Alto, CA 94303-0961
Tel: (650) 813-4800
Fax: (650) 813-4848

The attorney docket number for this application was formerly entered as 185875/US. It has since been changed to docket number 376956-003US (368532). Please use this new docket number in reference to this application for all future communications.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Assignee:	GRANTA BIOTECHNOLOGY LIMITED
Date:	<u>17th JUNE 2005</u>
Signed:	<u></u>
Print Name:	<u>JASON PETER BROWN</u>
Print Title:	<u>DIRECTOR</u>